New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Morten Persson, Palle Damkjær Rasmussen, Jacob Madsen, Michael Ploug, Andreas Kjaer

34 Citationer (Scopus)

Abstract

The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.
OriginalsprogEngelsk
TidsskriftNuclear Medicine and Biology
Vol/bind39
Udgave nummer7
Sider (fra-til)962-9
Antal sider8
ISSN0969-8051
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts'. Sammen danner de et unikt fingeraftryk.

Citationsformater